| 4:00–8:00 PM | Arrival and Registration | Riverview Lounge |
| 6:00–8:00 PM | Welcome Mixer | Riverview Lounge |
| 7:00–8:00 AM | Breakfast | Alberta/New Brunswick |
| 8:00–9:00 AM | Welcome and Keynote Address | Cascade Ballroom |
| Arun J. Sanyal, Virginia Commonwealth University Medical Center MASH and Fibrosis: What have we Learned from Clinical Trials? |
| 9:00–11:15 AM | The Origin of the Nile: What is the Culprit of MASH? | Cascade Ballroom |
| Mohammed Eslam, University of Sydney Nutritional, Non-Alcoholic or Metabolic associated Fatty Liver Disease? |
| Amalia Gastaldelli, Institute of Clinical Physiology Worsening of Metabolic Fluxes: From Hepatic Steatosis to MASH |
| Silvia C. Sookoian, CONICET. Universidad Maimonides MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics |
| 9:30–9:50 AM | Coffee Break | Riverview Lounge |
| 11:15–1:00 PM | Poster Setup | Alberta/New Brunswick |
| 11:15–5:00 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing | Alberta/New Brunswick |
| 2:30–4:30 PM | Workshop 1: Inflammation and Fibrosis: Novel Disease Mechanisms | Cascade Ballroom |
| KUO DU, Duke Universty Aging Promotes Metabolic Dysfunction-associated Steatotic Liver Disease by Inducing Ferroptotic Stress in Hepatocytes |
| Celine Hoffmann, CNRS Characterization and Purification of Hypertrophied Hepatic Stellate Cells and their Association with Liver Fibrosis |
| Xin (Tony) Tong, University of Michigan Medical School Activation of Hepatocyte E4BP4-OPN Axis Promotes Liver Fibrosis in Non-alcoholic Steatohepatitis |
| Clémence Schmitt, University of Montreal / IRCM Glucolipotoxicity Regulates the Secretion of Interleukin-6 Trans-Signaling Inhibitor, sgp130, Through Matrix Metalloproteases Shedding in Hepatic Stellate Cells |
| Kathryn Buscher, University of Michigan Glucose-mediated Control of STAT3 Activation in Fibrosis |
| William De Nardo, University of Melbourne Targeting the Endocrine Actions of a MASH-inducible Hepatic Stellate Cell Secreted Protein – a Worthwhile Venture |
| Tima Dehghani, insitro Interrogating the Effect of Fibrosis on Hepatocyte Transcriptome and Lipid Accumulation Phenotype |
| 4:30–5:00 PM | Coffee Available | Riverview Lounge |
| 5:00–7:00 PM | Steatotic Liver Disease: Multiple Phenotypes or Different Diseases? | Cascade Ballroom |
| Vincent WS Wong, Chinese University of Hong Kong Lean NAFLD: Molecular Mechanisms of MASH and Fibrosis |
| Julia Kozlitina, University of Texas Southwestern Medical Center Molecular Basis of Ethnic Differences in MASH and Fibrosis |
| Päivi Pajukanta, David Geffen School of Medicine at UCLA MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics |
| Lewis R. Roberts, Mayo Clinic Cirrhotic and Noncirrhotic: Mechanisms of Hepatocellular Carcinoma in SLD |
| Federica Tavaglione, Università Campus Bio-Medico di Roma Short Talk: Short Talk: A Data-Driven Cluster Analysis Identifies Distinct Types of Metabolic Dysfunction-Associated Steatotic Liver Disease |
| 7:00–8:00 PM | Social Hour with Lite Bites | Alberta/New Brunswick |
| 7:30–10:00 PM | Poster Session 1 | Alberta/New Brunswick |
| 7:00–8:00 AM | Breakfast | Alberta/New Brunswick |
| 8:00–11:00 AM | Preclinical Model of MASH Clinical Trials | Cascade Ballroom |
| Peter Olinga, University of Groningen Precision Slice Cut as a Preclinical Model of MASH |
| Jennifer L. Estall, Institut de Recherches Cliniques de Montréal Modeling MASH in Mice: Overcoming Problems in Translation |
| Elia Casirati, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Short Talk: Short Talk: PNPLA3 p.I148M Variant Affects Lipid Droplets Number and Size in Patient-derived Liver Organoids |
| Marcel den Hoed, Uppsala University Short Talk: Short Talk: Characterizing 99 Cardiometabolic Candidate Genes for a Role in MASLD Using CRISPR/Cas9, in vivo Imaging and Deep Learning in Zebrafish Larvae |
| Francesca M Lazzeri-Barcelo, Karolinska Institutet Short Talk: Short Talk: Non-Invasive in vivo Imaging of Liver Spheroids Engrafted in the Anterior Chamber of the Eye |
| Scott Heyward, BioIVT Short Talk: Short Talk: Using siRNA Generated Isogenic Pairs in a Micropatterned Primary Hepatocyte Co-culture (HEPATOPAC) to Define the Role of CIDEB in a Model of Hepatic Steatosis |
| 9:00–9:20 AM | Coffee Break | Riverview Lounge |
| 11:00–1:00 PM | Poster Setup | Alberta/New Brunswick |
| 11:00–5:00 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing | Alberta/New Brunswick |
| 3:00–4:30 PM | Career Roundtable | Cascade Ballroom |
| Lewis R. Roberts, Mayo Clinic Professor |
| Bani Mukhopadhyay, National Institutes of Health Staff Scientist |
| 4:30–5:00 PM | Coffee Available | Riverview Lounge |
| 5:00–7:00 PM | Current Status and Future of Endpoints to Assess Efficacy in Clinical Trials | Cascade Ballroom |
| Alina M. Allen, Mayo Clinic Identifying Populations at Risk for Liver Events – is MASH with Fibrosis by Histology the only Way? |
| Michael Charlton, University of Chicago Medicine Is Regression of Fibrosis the Only Surrogate for Outcomes Benefit? |
| Manal F. Abdelmalek, Mayo Clinic Assessing Response to Drug Treatment Beyond Liver Biopsy |
| Francois Pattou, Lille University Short Talk: Short Talk: Resolution of MASH with No Worsening of Fibrosis after Bariatric Surgery Improves 15-year Survival |
| 7:00–8:00 PM | Social Hour with Lite Bites | Alberta/New Brunswick |
| 7:30–10:00 PM | Poster Session 2 | Alberta/New Brunswick |
| 7:00–8:00 AM | Breakfast | Alberta/New Brunswick |
| 8:00–11:00 AM | Genetic Insights into MASH, Fibrosis and Hepatocellular Carcinoma | Cascade Ballroom |
| Stefano Romeo, University of Gothenburg Human Genetics of Steatotic Liver Disease: What Have We Learned So Far? |
| Luca Vittorio C Valenti, University of Milan PNPLA3, Estrogens and SLD Progression in Women |
| Luca Lotta, Regeneron Pharmaceuticals Inc. Human Genetics of Liver Disease and Implications for Therapeutic Development |
| Eleonora Scorletti, University of Pennsylvania Short Talk: Short Talk: Association of a Glucagon-like Peptide-1 Receptor Gene Variant with Metabolic Dysfunction Associated Liver Disease (MASLD) |
| Ype de Jong, Weill Cornell Medicine Short Talk: Short Talk: Overexpressing PNPLA3-148I or ABHD5 Differentially Protects Primary Human Hepatocytes from Hypercaloric Diet-induced Steatosis Depending on their PNPLA3 Genotype |
| Allison Wing, National Institutes of Health Short Talk: Short Talk: Hsd17b13 Loss Adversely Impacts Glucose-insulin Metabolism |
| Justin Crane, Pfizer Short Talk: Short Talk: Murine HSD17B13 Does Not Control Liver Steatosis and Modestly Impacts Fibrosis Under Specific Dietary Conditions |
| 9:00–9:20 AM | Coffee Break | Riverview Lounge |
| 11:00–5:00 PM | On Own for Lunch |
| 2:30–4:30 PM | Workshop 2: Therapeutics: Novel Drug Candidates | Cascade Ballroom |
| Haressh Sajiir, Mater Research Institute - The University of Queensland Development of Liver-targeted Interleukin-22 for Metabolic Dysfunction Associated Steatohepatitis |
| Erik J. Tillman, Akero Therapeutics Efruxifermin Significantly Improved Collagen Biomarkers Consistent with Beneficial ECM Remodeling in Patients with F2-F3 Fibrosis Due to MASH |
| Yaron Rotman, NIDDK, National Institutes of Health The Postprandial Plasma Proteome is Altered in People with Metabolic Dysfunction-associated Steatotic Liver Disease |
| Reza Zarnegar, University of Pittsburgh, School of Medicine A Novel Humanized Model of NASH and its Treatment with META4 a Potent Agonist of MET |
| Brenna Pearson-Gallion, Louisiana State University Health Sciences Shreveport EphA2 Promotes Inflammation and Alters Hepatocyte Metabolism to Enhance Metabolic Dysfunction-associated Steatotic Liver Disease |
| Christy M Gliniak, University of Texas Southwestern Medical Center Methionine Aminopeptidase 2 (MetAP2) Regulates Anabolic and Catabolic Metabolism in Hepatocytes Through Ancient Mechanisms That Control Protein Translation |
| Matti Hoch, University of Rostock Investigating MASLD Using a Multi-level Computational Model |
| Yuanyuan Qin, UCSF TMEM55B deficiency alters lysosomal fatty acid trafficking and induces metabolic dysfunction associated steatohepatitis (MASH) |
| 4:30–5:00 PM | Coffee Available | Riverview Lounge |
| 5:00–6:45 PM | Opportunities and Challenges of Precision Medicine in Steatotic Liver Disease | Cascade Ballroom |
| Heather Hsu, Inipharm HSD17B13 Inhibition with INI-822 Phenocopies the Human HSD17B13 Protective Allele |
| Gregory Tesz, Pfizer Targeting PNPLA3 148M to Treat MASH and Fibrosis |
| Shuang Wang, Icahn School of Medicine at Mount Sinai Hepatic Stellate Cell Plasticity and Maladaptive Fibrogenic Memory in CLD |
| 6:45–7:00 PM | Meeting Wrap-Up: Outcomes and Future Directions (Organizers) | Cascade Ballroom |
| 7:00–8:00 PM | Social Hour with Lite Bites | Alberta/New Brunswick |
| 8:00–11:00 PM | Entertainment |
| 8:00–11:00 PM | Cash Bar | Alberta/New Brunswick |
| 7:00–11:59 PM | Departure |